Menu Search
Equities

BioMarin Pharmaceutical Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
1BMRN:MIL

BioMarin Pharmaceutical Inc

Actions
  • Price (EUR)48.19
  • Today's Change-0.78 / -1.59%
  • Shares traded15.00
  • 1 Year change-22.60%
  • Beta0.2580
Data delayed at least 15 minutes, as of Feb 04 2026 12:25 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.

  • Revenue in USD (TTM)3.09bn
  • Net income in USD520.42m
  • Incorporated1996
  • Employees3.04k
  • Location
    BioMarin Pharmaceutical Inc770 Lindaro StreetSAN RAFAEL 94901United StatesUSA
  • Phone+1 (415) 506-6700
  • Fax+1 (302) 636-5454
  • Websitehttps://www.biomarin.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		BMRN:NSQ since
announced		Transaction
value
Amicus Therapeutics IncAnnounced19 Dec 202519 Dec 2025Announced11.90%4.79bn
Inozyme Pharma IncDeal completed16 May 202516 May 2025Deal completed-0.24%274.36m
Data delayed at least 15 minutes, as of Feb 06 2026 21:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.